Please assess the completion status of the following clinical trial:

Trial Title: Intra-arterial Magnesium Administration for Acute Stroke

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with acute cerebral ischemia due to ICA or MCA occlusion,~2. Patient's clinical attending physician plans mechanical embolectomy procedure as part of routine clinical care.~3. Age 21-95.~Exclusion Criteria:~1. Severe renal impairment with creatinine 3.0 or higher,~2. Myasthenia gravis,~3. Second or third degree heart block without a pacemaker in place,~4. Technical inability to navigate microcatheter to target clot,~5. Patient already enrolled in another experimental treatment trial. Exclusion criteria 1-3 are all contraindications to magnesium therapy.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Regional Intra-arterial Magnesium 0.75g (Type: EXPERIMENTAL): Regional Intra-arterial magnesium only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
- Regional Intra-arterial magnesium 1.5g (Type: EXPERIMENTAL): Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
- Regional/ Distal (75/25%) Magnesium 1.5g (Type: EXPERIMENTAL): Regional/ Distal intra-arterial magnesium (75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
- Regional/ Distal (50/50%) Magnesium 1.5g (Type: EXPERIMENTAL): Regional/ Distal intra-arterial magnesium (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients

Based on this trial design, predict the completion outcome and termination type (if applicable).